GCA
IRWD icon

Gideon Capital Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Gideon Capital Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,387
Closed -$191K – 330
2017
Q1 		$191K Buy
+13,387
New +$183K 0.11% 375

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Gideon Capital Advisors's IRWD Position: Q2 2017 in Review

Gideon Capital Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2017, closing a stake of 13,387 shares — an estimated $191K sold.

Gideon Capital Advisors first reported a position in IRWD in Q1 2017 and held it in 1 quarter. The position peaked at $191K in Q1 2017. 167 funds tracked by Wall St. Rank hold IRWD as of Q2 2017.

  • Gideon Capital Advisors reported no remaining Ironwood Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Gideon Capital Advisors sold 13,387 Ironwood Pharmaceuticals shares in Q2 2017, an estimated $191K.
  • Gideon Capital Advisors first reported a position in Ironwood Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Gideon Capital Advisors's Ironwood Pharmaceuticals position peaked at $191K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2017.

Based on Gideon Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.